Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions

PurposeThe purpose of the present study was to evaluate whether 2-fluoro[fluorine-18]-2-deoxy-d-glucose (F-18 FDG) positron emission tomography (PET) could differentiate malignant and benign bone lesions and whether obtaining delayed F-18 FDG PET images could improve the accuracy of the technique.MethodsIn a prospective study, 67 patients with bone lesions detected by computed tomography (CT) or magnetic resonance imaging were included. Whole body PET/CT imaging was performed at 1 h (early) after the F-18 FDG injection and delayed imaging at 2 h post injection was performed only in the abnormal region. Semiquantitative analysis was performed using maximum standardized uptake value (SUVmax), obtained from early and delayed images (SUVmaxE and SUVmaxD, respectively). The retention index (RI) was calculated according to the equation: RI = (SUVmaxD − SUVmaxE) × 100/SUVmaxE. Histopathology of surgical specimens and follow-up data were used as reference criteria. The SUVmaxE and RI were compared between benign and malignant lesions.ResultsThe final diagnoses revealed 53 malignant bone lesions in 37 patients and 45 benign lesions in 30 patients. There were statistically significant differences in the SUVmaxE between the malignant and benign lesions (P = 0.03). The mean SUVmaxE was 6.8 ± 4.7 for malignant lesions and 4.5 ± 3.3 for benign lesions. However, a considerable overlap in the SUVmaxE was observed between some benign and malignant tumors. With a cutoff value of 2.5 for the SUVmaxE, the sensitivity, specificity, and accuracy were 96.0%, 44.0%, and 72.4%, respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 67.1% and 90.9%, respectively. There were significant differences in the RI between the malignant and benign lesions (P = 0.004). But there was overlap between the two groups. The mean RI was 7 ± 11 for the benign lesions and 18 ± 11 for the malignant lesions. When an RI of 10 was used as the cutoff point, the sensitivity, specificity, and accuracy were 90.6%, 76.0%, and 83.7.0%, respectively. The PPV and NPV were 81.4% and 87.1%, respectively.ConclusionsThe results of this study indicate that dual-time point F-18 FDG PET may provide more help in the differentiation of malignant tumors from benign ones.

[1]  Y. Nishiyama,et al.  Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer , 2008, Annals of nuclear medicine.

[2]  R P Williams,et al.  Noninvasive grading of musculoskeletal tumors using PET. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  F. Feldman,et al.  18FDG PET scanning of benign and malignant musculoskeletal lesions , 2003, Skeletal Radiology.

[5]  O. Shon,et al.  The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors , 2008, Annals of nuclear medicine.

[6]  J. Goo,et al.  Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. , 2000, Radiology.

[7]  D. Delbeke,et al.  Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. , 1996, Chest.

[8]  L. Colomo,et al.  Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma , 2008, Journal of magnetic resonance imaging : JMRI.

[9]  J. Hatazawa,et al.  Evaluation of delayed18F-FDG PET in differential diagnosis for malignant soft-tissue tumors , 2006 .

[10]  Shih-Ya Ma,et al.  Delayed 18F-FDG PET for Detection of Paraaortic Lymph Node Metastases in Cervical Cancer Patients , 2003 .

[11]  L. Griffeth,et al.  PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. , 1992, Radiology.

[12]  J. Spitzer,et al.  Contribution of different organs to increased glucose consumption after endotoxin administration. , 1987, The Journal of biological chemistry.

[13]  R. Erlemann.  Imaging and differential diagnosis of primary bone tumors and tumor-like lesions of the spine. , 2006, European journal of radiology.

[14]  K. Takagishi,et al.  FDG-PET for evaluating musculoskeletal tumors: a review , 2003, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[15]  S. Larson,et al.  Metabolic imaging of human extremity musculoskeletal tumors by PET. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Hatazawa,et al.  Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. , 2006, Annals of nuclear medicine.

[17]  C. Sahlmann,et al.  Dual time point 2-[18F]fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis , 2004, Nuclear medicine communications.

[18]  Kazuo Awai,et al.  Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. , 2006, Radiology.

[19]  Cyrill Burger,et al.  The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  J. Hodler,et al.  The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  J. V. van Horn,et al.  Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  A. Alavi,et al.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck , 1999, European Journal of Nuclear Medicine.

[23]  A. Alavi,et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Alavi,et al.  Dual-Time Point FDG PET Imaging in the Evaluation of Pulmonary Nodules With Minimally Increased Metabolic Activity , 2007, Clinical nuclear medicine.

[25]  U. Exner,et al.  PET-positive fibrous dysplasia - a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery , 2007, Skeletal Radiology.

[26]  S. Reske,et al.  Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Abass Alavi,et al.  Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  R. Coleman,et al.  Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry , 2008, Journal of Nuclear Medicine.

[29]  Jonathan Goldin,et al.  Accuracy of PET/CT in characterization of solitary pulmonary lesions. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  M. J. Fusselman,et al.  Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. , 1996, Radiology.

[31]  J Aoki,et al.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. , 2001, Radiology.

[32]  M. Bredella,et al.  Use of FDG-PET in differentiating benign from malignant compression fractures , 2008, Skeletal Radiology.